AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 101 min read$ELAN

VanHimbergen Robert M purchased $97K of ELAN

VanHimbergen Robert M (EVP and CFO) purchased 4,200 shares of Elanco Animal Health Inc (ELAN) at $23.08 on 2026-08-07.

Original reporting
SEC EDGAR · VanHimbergen Robert M
Published Aug 10, 2026, 8:14 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ELAN
Bullish
low confidence
Mentioned
$ELAN
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELANBullishLow
01

Why it matters

The newest information is the CFO’s open-market purchase details (shares, price, total value, and post-transaction holdings).

02

Market read

This is a fresh insider-buy disclosure that may slightly support sentiment, but it does not introduce new operational or financial guidance.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it still provides no rationale for the buy, and the dollar amount is relatively small versus company market cap.

Relevance 4/10Novelty 5/10Timing: filed after-hours on 2026-08-10 (SEC Form 4 disclosure)

Background

The article is an SEC Form 4 insider transaction disclosure for Elanco Animal Health Inc.

Company-level read

Ticker impact

$ELANBullishLow confidence
Context

Elanco Animal Health CFO VanHimbergen bought 4,200 shares open-market at $23.0776 on 2026-08-07, filing disclosed 2026-08-10.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by additional disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction with a defined trade size and price, but it does not include new company guidance, contracts, litigation, or operational changes.

Market effects

Sector

No direct sector read-through; this is a single-company insider transaction without broader industry information.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider purchases can be routine liquidity or diversification actions and do not necessarily reflect a change in fundamentals.

Key entities

  • issuer
    Elanco Animal Health Inc

    Subject of the Form 4 insider transaction disclosure.

  • insider
    VanHimbergen Robert M

    EVP and CFO who reported the open-market purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ELAN insider trading history →

Related articles

AUG 13
$ELANMed

Elanco rating upgraded by Fitch on deleveraging progress

Fitch Ratings upgraded Elanco Animal Health’s (NYSE:ELAN) Long-Term Issuer Default Rating to BB+ from BB and raised senior secured to BBB- from BB+ and senior unsecured to BB+ from BB, with a stable outlook. Fitch cited balance-sheet deleveraging, share gains, and cash flow. It projects EBITDA leverage below 3.5x, debt down about $650M since 2024, and free cash flow rising from $345M (2026) to ~$575M (2028).

investing.com4 min
AUG 12
$ELANHighAI 9/10

Elanco (ELAN) Q2 2026 Earnings Call Transcript

Elanco Animal Health (ELAN) reported Q2 2026 revenue of $1.368B, up 8% organic constant currency, and adjusted EBITDA of $288M (+21%). Adjusted EPS was $0.34 (+31%). Management raised 2026 revenue guidance to $5.09B-$5.14B and adjusted EPS to $1.10-$1.16, citing innovation sales led by Zenrelia and Credelio Quattro.

fool.com6 min
AUG 10
$ELANHighAI 8/10

ELAN Stock Jumps As Earnings Beat Fuels Bullish Guidance

Elanco Animal Health (NYSE: ELAN) shares rose about 3.4% after Q2 2026 results beat expectations and management raised guidance. Elanco reported revenue of $1.37B vs $1.31B expected and adjusted EPS of $0.34 vs $0.27, with 2026 guidance of EPS $1.10–$1.16 and revenue $5.09B–$5.14B. Analysts including KeyBanc, UBS and Citi raised targets to $30–$34.

stockstotrade.com4 min
AUG 9
$ELANMedAI 8/10

Elanco Animal Health Q2 Earnings Call Highlights

Elanco Animal Health (NYSE:ELAN) reported Q2 updates on pet and farm results. Credelio Quattro gained market share, with product in over half of U.S. clinics. Early Befrena demand was described as soft-launched in May, with supply constrained until early 2027. AdTab international OTC parasiticides sales rose over 30%. Elanco raised 2026 innovation revenue target to about $1.25B and guided FY revenue $5.09B-$5.14B, adjusted EBITDA $1.01B-$1.035B, adjusted EPS $1.10-$1.16.

yahoo.com7 min
AUG 5
$ELANMedAI 8/10

Elanco Animal Health Boosts FY26 Outlook; Stock Up 7% - Update

Elanco Animal Health (ELAN) reported Q2 results and issued Q3 guidance, expecting adjusted EPS of $0.19 to $0.22 on revenue of $1.195B to $1.220B, with 5% to 7% organic constant-currency growth. For FY2026, it raised outlook to adjusted EPS $1.10 to $1.16 on revenue $5.09B to $5.14B, up from prior $1.03 to $1.09 on $5.01B to $5.085B. Shares rose to $27.37.

rttnews.com2 min